KR102088078B1 - 신경퇴행성 질환을 치료하기 위한 방법 및 조성물 - Google Patents

신경퇴행성 질환을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102088078B1
KR102088078B1 KR1020157014255A KR20157014255A KR102088078B1 KR 102088078 B1 KR102088078 B1 KR 102088078B1 KR 1020157014255 A KR1020157014255 A KR 1020157014255A KR 20157014255 A KR20157014255 A KR 20157014255A KR 102088078 B1 KR102088078 B1 KR 102088078B1
Authority
KR
South Korea
Prior art keywords
compound
alkyl
disease
composition
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157014255A
Other languages
English (en)
Korean (ko)
Other versions
KR20150087844A (ko
Inventor
승-영 리우
우-체 원
식-밍 천
Original Assignee
골든 바이오테크놀러지 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 골든 바이오테크놀러지 코포레이션 filed Critical 골든 바이오테크놀러지 코포레이션
Publication of KR20150087844A publication Critical patent/KR20150087844A/ko
Application granted granted Critical
Publication of KR102088078B1 publication Critical patent/KR102088078B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/835—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups having unsaturation outside an aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020157014255A 2012-11-21 2013-11-18 신경퇴행성 질환을 치료하기 위한 방법 및 조성물 Active KR102088078B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261729295P 2012-11-21 2012-11-21
US61/729,295 2012-11-21
PCT/US2013/070625 WO2014081675A1 (en) 2012-11-21 2013-11-18 Methods and compositions for treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
KR20150087844A KR20150087844A (ko) 2015-07-30
KR102088078B1 true KR102088078B1 (ko) 2020-03-12

Family

ID=50728525

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157014255A Active KR102088078B1 (ko) 2012-11-21 2013-11-18 신경퇴행성 질환을 치료하기 위한 방법 및 조성물

Country Status (13)

Country Link
US (1) US9861592B2 (https=)
EP (1) EP2922534B1 (https=)
JP (1) JP6407876B2 (https=)
KR (1) KR102088078B1 (https=)
CN (1) CN104968339B (https=)
AU (1) AU2013348248B2 (https=)
BR (1) BR112015011798A2 (https=)
CA (1) CA2892084C (https=)
ES (1) ES2788598T3 (https=)
MX (1) MX2015006337A (https=)
TW (1) TWI559917B (https=)
WO (1) WO2014081675A1 (https=)
ZA (1) ZA201504292B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037566A1 (en) * 2014-09-09 2016-03-17 Ching-Feng Weng Use of antroqiononol for treating obesity, and process for preparation of antroquinonol
CN107847473B (zh) * 2015-05-29 2021-08-10 香港大学 新型神经保护性和神经修复性n-炔丙基咖啡酰胺(paca)及作为神经变性疾病的疗法的用途
TW201733573A (zh) * 2016-03-25 2017-10-01 郭盈妤 牛樟芝化合物用於製備治療及預防神經退行性疾病之藥物的用途
CN107296805A (zh) * 2016-04-14 2017-10-27 郭盈妤 牛樟芝化合物及其萃取物用于制备治疗及预防神经退行性疾病的药物的用途
US11406605B2 (en) * 2017-12-20 2022-08-09 Golden Biotechnology Corporation Therapeutic compositions for treating pancreatic cancer
WO2019160150A1 (ja) * 2018-02-19 2019-08-22 國子 草間 バレロラクトン（Ｖａｌｅｒｏｌａｃｔｏｎｅ）系新規化合物、及び、医薬
TW202038981A (zh) * 2018-11-28 2020-11-01 薩摩亞商吉亞生技控股股份有限公司 治療失智症的組合物及方法
US11111263B2 (en) * 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
CN110200998B (zh) * 2019-05-24 2021-04-16 清华大学 神经元来源外泌体的制备及其在治疗老年痴呆症中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047199A1 (en) 1999-02-10 2000-08-17 Meiji Dairies Corporation Use of a cyclohexenone long-chain alcohol for treating neurodegenerative diseases

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4031893A (en) 1976-05-14 1977-06-28 Survival Technology, Inc. Hypodermic injection device having means for varying the medicament capacity thereof
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5540664A (en) 1993-05-27 1996-07-30 Washington Biotech Corporation Reloadable automatic or manual emergency injection system
US5358489A (en) 1993-05-27 1994-10-25 Washington Biotech Corporation Reloadable automatic or manual emergency injection system
AU1994295A (en) 1994-05-16 1995-12-05 Washington Biotech Corporation Modular automatic or manual emergency medicine injection system
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US7544189B2 (en) 2000-10-10 2009-06-09 Meridian Medical Technologies, Inc. Needle and hub assembly for automatic injector
EP2418191A1 (en) * 2005-02-28 2012-02-15 Meiji Co., Ltd. Long-chain trimethoxyphenylalkanol derivatives, and pharmaceuticals comprising the same
TW200829234A (en) * 2007-01-08 2008-07-16 Golden Biotechnology Corp Antrodia camphorata isophorone extract
TWI394573B (zh) * 2007-06-14 2013-05-01 國鼎生物科技股份有限公司 Application of Cynanchum auranthone Cyclohexenone Compounds in the Preparation of Drugs for Liver Protection
US8309611B2 (en) * 2010-09-20 2012-11-13 Golden Biotechnology Corporation Methods and compositions for treating lung cancer
SE1350211A1 (sv) * 2012-02-23 2013-08-24 Golden Biotechnology Corp Metoder och kompositioner för behandling av cancermetastaser
JP6234990B2 (ja) 2012-03-26 2017-11-22 ゴールデン バイオテクノロジー コーポレーション 動脈硬化性血管疾患を処置するための方法及び組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047199A1 (en) 1999-02-10 2000-08-17 Meiji Dairies Corporation Use of a cyclohexenone long-chain alcohol for treating neurodegenerative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Planta Medica, 78(17), 1813-1823, 2012.

Also Published As

Publication number Publication date
TW201440758A (zh) 2014-11-01
AU2013348248B2 (en) 2018-06-14
AU2013348248A1 (en) 2015-07-02
EP2922534B1 (en) 2020-04-08
TWI559917B (en) 2016-12-01
ES2788598T3 (es) 2020-10-22
CA2892084A1 (en) 2014-05-30
CN104968339B (zh) 2019-06-11
WO2014081675A1 (en) 2014-05-30
BR112015011798A2 (pt) 2017-07-11
US9861592B2 (en) 2018-01-09
MX2015006337A (es) 2015-09-07
EP2922534A1 (en) 2015-09-30
EP2922534A4 (en) 2016-05-11
JP6407876B2 (ja) 2018-10-17
HK1215548A1 (zh) 2016-09-02
US20140142194A1 (en) 2014-05-22
KR20150087844A (ko) 2015-07-30
ZA201504292B (en) 2017-04-26
CN104968339A (zh) 2015-10-07
CA2892084C (en) 2020-11-10
JP2016500074A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
KR102088078B1 (ko) 신경퇴행성 질환을 치료하기 위한 방법 및 조성물
RU2671492C2 (ru) Композиции, содержащие берберин или его аналоги для лечения кожных заболеваний, связанных с розацеа или с покраснением лица
KR102054038B1 (ko) 백혈병의 치료방법 및 치료용 조성물
CN103908445A (zh) 化合物在制备用于治疗糖尿病的组成物上的用途
CN103796647A (zh) 用于治疗脑癌的方法和组合物
TW201533014A (zh) 使用環己烯酮化合物之治療方法及組成物
AU2012387970B2 (en) Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof
TWI746701B (zh) 用於治療異位性皮膚炎的方法和組成物
US20130203861A1 (en) Methods and compositions for treating ovarian cancer
HK1215548B (zh) 用於治疗神经变性疾病的方法和组合物
CN121370926A (zh) 一种治疗和/或预防抑郁症的药物组合物及其制备方法、应用
CN103948577A (zh) 化合物在制备用于治疗、减缓或处理骨癌疼痛的组成物的用途
KR20230008711A (ko) Rna 바이러스 유도된 질환을 치료하기 위한 방법 및 조성물
HK40008168A (en) Methods and compositions for treating atopic dermatitis
HK40008168B (en) Methods and compositions for treating atopic dermatitis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7